End-of-day quote
Nigerian S.E.
03:30:00 16/05/2024 am IST
|
5-day change
|
1st Jan Change
|
4.05
NGN
|
0.00%
|
|
0.00%
|
+44.64%
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Capitalization
1 |
80.66
|
544
|
494.6
|
484.7
|
1,968
|
2,146
|
Enterprise Value (EV)
1 |
298.1
|
539.9
|
493.5
|
539.9
|
2,083
|
2,268
|
P/E ratio
|
-0.45
x
|
-2.86
x
|
-4.72
x
|
-4.52
x
|
-21
x
|
-20
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
0.53
x
|
3.94
x
|
5.74
x
|
3.97
x
|
14
x
|
13.9
x
|
EV / Revenue
|
1.97
x
|
3.91
x
|
5.73
x
|
4.43
x
|
14.8
x
|
14.6
x
|
EV / EBITDA
|
-3.38
x
|
-3.91
x
|
-6.88
x
|
-7.67
x
|
-42.6
x
|
-47.1
x
|
EV / FCF
|
-3.07
x
|
-2.87
x
|
13.4
x
|
-29.2
x
|
-83
x
|
67.6
x
|
FCF Yield
|
-32.5%
|
-34.8%
|
7.48%
|
-3.42%
|
-1.2%
|
1.48%
|
Price to Book
|
-2.14
x
|
2.14
x
|
3.32
x
|
11.6
x
|
1.85
x
|
2.24
x
|
Nbr of stocks (in thousands)
|
1,52,180
|
9,89,162
|
9,89,162
|
9,89,162
|
9,89,160
|
9,89,160
|
Reference price
2 |
0.5300
|
0.5500
|
0.5000
|
0.4900
|
1.990
|
2.170
|
Announcement Date
|
08/05/18
|
02/04/19
|
29/05/20
|
01/04/21
|
30/03/22
|
13/06/23
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Net sales
1 |
151.4
|
138.2
|
86.11
|
122
|
140.6
|
154.9
|
EBITDA
1 |
-88.07
|
-138.1
|
-71.77
|
-70.39
|
-48.84
|
-48.15
|
EBIT
1 |
-112.6
|
-167.3
|
-104.3
|
-102.4
|
-80.19
|
-86.81
|
Operating Margin
|
-74.39%
|
-121.07%
|
-121.11%
|
-83.93%
|
-57.03%
|
-56.06%
|
Earnings before Tax (EBT)
1 |
-181.2
|
-188.6
|
-104.3
|
-106.9
|
-93.46
|
-106.4
|
Net income
1 |
-181.2
|
-190.1
|
-104.7
|
-107.3
|
-93.93
|
-107.5
|
Net margin
|
-119.69%
|
-137.55%
|
-121.61%
|
-87.99%
|
-66.8%
|
-69.41%
|
EPS
2 |
-1.191
|
-0.1922
|
-0.1059
|
-0.1085
|
-0.0950
|
-0.1087
|
Free Cash Flow
1 |
-97
|
-188
|
36.89
|
-18.46
|
-25.09
|
33.54
|
FCF margin
|
-64.08%
|
-136.02%
|
42.84%
|
-15.13%
|
-17.84%
|
21.66%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
08/05/18
|
02/04/19
|
29/05/20
|
01/04/21
|
30/03/22
|
13/06/23
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Net Debt
1 |
217
|
-
|
-
|
55.2
|
114
|
122
|
Net Cash position
1 |
-
|
4.12
|
1.08
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-2.469
x
|
-
|
-
|
-0.7841
x
|
-2.342
x
|
-2.53
x
|
Free Cash Flow
1 |
-97
|
-188
|
36.9
|
-18.5
|
-25.1
|
33.5
|
ROE (net income / shareholders' equity)
|
-343%
|
-176%
|
-52%
|
-113%
|
-16.9%
|
-10.6%
|
ROA (Net income/ Total Assets)
|
-14.7%
|
-19.3%
|
-13.2%
|
-15.3%
|
-5%
|
-3.41%
|
Assets
1 |
1,231
|
984.6
|
793.4
|
701.5
|
1,877
|
3,152
|
Book Value Per Share
2 |
-0.2500
|
0.2600
|
0.1500
|
0.0400
|
1.080
|
0.9700
|
Cash Flow per Share
2 |
0.0400
|
0
|
0
|
0
|
0.0100
|
0.0100
|
Capex
1 |
15.6
|
35.1
|
1.73
|
11.5
|
3.89
|
1.37
|
Capex / Sales
|
10.3%
|
25.39%
|
2%
|
9.39%
|
2.77%
|
0.89%
|
Announcement Date
|
08/05/18
|
02/04/19
|
29/05/20
|
01/04/21
|
30/03/22
|
13/06/23
|
|
1st Jan change
|
Capi.
|
---|
| +44.64% | 2.64M | | +21.98% | 43.92B | | +24.56% | 23.09B | | +19.25% | 15.35B | | +14.03% | 13.61B | | +46.40% | 12.02B | | -10.14% | 7B | | -0.05% | 6.79B | | -8.87% | 5.73B | | +13.88% | 5.6B |
Generic Pharmaceuticals
|